Indiana Medicaid spends 10.7% of budget on Rxs; a "good investment," ex-Gov. Bayh tells PhRMA.
INDIANA MEDICAID DRUG EXPENDITURE OF 10.7% IS "GOOD INVESTMENT," former Indiana Gov. Evan Bayh (D) told the Pharmaceutical Research & Manufacturers of America annual meeting March 24 in Boca Raton, Fla. "Pharmaceuticals, because we had a very strong belief that they were cost-effective, in fact have increased as a percentage of our state Medicaid expenditures," Bayh said. "We think of that as a sound long-term investment not only in health but in cost-effectiveness."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth